Latest Insider Transactions at Corcept Therapeutics Inc (CORT)
This section provides a real-time view of insider transactions for Corcept Therapeutics Inc (CORT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CORCEPT THERAPEUTICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CORCEPT THERAPEUTICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 21
2023
|
Joseph Douglas Lyon |
BUY
Exercise of conversion of derivative security
|
Direct |
4,588
+18.8%
|
$41,292
$9.81 P/Share
|
|
Aug 14
2023
|
David L Mahoney |
SELL
Open market or private sale
|
Indirect |
25,000
-24.08%
|
$750,000
$30.95 P/Share
|
|
Aug 14
2023
|
Hazel Hunt Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,455
-21.85%
|
$613,650
$30.89 P/Share
|
|
Aug 08
2023
|
Hazel Hunt Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,545
-23.99%
|
$886,350
$30.48 P/Share
|
|
Aug 08
2023
|
Hazel Hunt Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+28.88%
|
$150,000
$3.02 P/Share
|
|
Aug 07
2023
|
Joseph Douglas Lyon |
BUY
Exercise of conversion of derivative security
|
Direct |
412
+7.43%
|
$3,296
$8.27 P/Share
|
|
Aug 07
2023
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
412
-8.03%
|
$12,772
$31.22 P/Share
|
|
Aug 07
2023
|
Daniel N Swisher Jr |
SELL
Open market or private sale
|
Direct |
2,850
-88.6%
|
$85,500
$30.15 P/Share
|
|
Aug 07
2023
|
Daniel N Swisher Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,850
+34.29%
|
$17,100
$6.21 P/Share
|
|
Jul 17
2023
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.09%
|
$10,000
$1.92 P/Share
|
|
Jul 17
2023
|
G Leonard Baker Jr Director |
SELL
Bona fide gift
|
Indirect |
0
|
-
|
|
Jun 13
2023
|
Gary Charles Robb Chief Business Officer |
SELL
Bona fide gift
|
Direct |
600
-2.91%
|
-
|
|
Jun 08
2023
|
Gary Charles Robb Chief Business Officer |
BUY
Bona fide gift
|
Indirect |
2,175
+8.25%
|
-
|
|
Jun 08
2023
|
Gary Charles Robb Chief Business Officer |
SELL
Bona fide gift
|
Direct |
3,550
-3.13%
|
-
|
|
Jun 06
2023
|
Joseph Douglas Lyon |
SELL
Open market or private sale
|
Direct |
10,000
-66.09%
|
$230,000
$23.6 P/Share
|
|
Jun 06
2023
|
Joseph Douglas Lyon |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+39.79%
|
$110,000
$11.35 P/Share
|
|
Jun 01
2023
|
Sean Maduck |
BUY
Grant, award, or other acquisition
|
Direct |
3,316
+2.61%
|
$36,476
$11.49 P/Share
|
|
Jun 01
2023
|
Atabak Mokari Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,302
+20.26%
|
$36,322
$11.49 P/Share
|
|
Jun 01
2023
|
Joseph Douglas Lyon |
BUY
Grant, award, or other acquisition
|
Direct |
2,822
+24.53%
|
$31,042
$11.49 P/Share
|
|
Jun 01
2023
|
Gary Charles Robb Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,182
+8.3%
|
$46,002
$11.49 P/Share
|
|
May 10
2023
|
Gary Charles Robb Chief Business Officer |
SELL
Open market or private sale
|
Direct |
14,000
-41.18%
|
$336,000
$24.07 P/Share
|
|
May 09
2023
|
Gary Charles Robb Chief Business Officer |
SELL
Open market or private sale
|
Direct |
30,000
-46.88%
|
$690,000
$23.87 P/Share
|
|
May 08
2023
|
David L Mahoney |
SELL
Payment of exercise price or tax liability
|
Indirect |
2,197
-0.18%
|
$50,531
$23.76 P/Share
|
|
May 08
2023
|
David L Mahoney |
BUY
Exercise of conversion of derivative security
|
Indirect |
30,000
+2.36%
|
$30,000
$1.74 P/Share
|
|
May 05
2023
|
Gary Charles Robb Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
60,586
-48.63%
|
$1,454,064
$24.07 P/Share
|
|
May 05
2023
|
Gary Charles Robb Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
105,000
+36.79%
|
$210,000
$2.61 P/Share
|
|
Mar 01
2023
|
Sean Maduck |
BUY
Grant, award, or other acquisition
|
Direct |
2,920
+2.43%
|
$26,280
$9.93 P/Share
|
|
Mar 01
2023
|
Joseph Douglas Lyon |
BUY
Grant, award, or other acquisition
|
Direct |
2,310
+41.67%
|
$20,790
$9.93 P/Share
|
|
Mar 01
2023
|
William Guyer Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,944
+27.13%
|
$26,496
$9.93 P/Share
|
|
Mar 01
2023
|
Gary Charles Robb Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,200
+7.86%
|
$28,800
$9.93 P/Share
|
|
Mar 01
2023
|
Atabak Mokari Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,520
+27.08%
|
$22,680
$9.93 P/Share
|
|
Dec 01
2022
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
625
-1.09%
|
$15,625
$25.28 P/Share
|
|
Dec 01
2022
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
625
+1.08%
|
$1,875
$3.29 P/Share
|
|
Nov 23
2022
|
Gary Charles Robb Chief Business Officer |
SELL
Open market or private sale
|
Direct |
186
-0.87%
|
$4,836
$26.03 P/Share
|
|
Nov 22
2022
|
Gary Charles Robb Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,814
-18.41%
|
$125,164
$26.03 P/Share
|
|
Nov 18
2022
|
Gary Charles Robb Chief Business Officer |
SELL
Open market or private sale
|
Direct |
13,401
-33.89%
|
$348,426
$26.43 P/Share
|
|
Nov 17
2022
|
Gary Charles Robb Chief Business Officer |
SELL
Open market or private sale
|
Direct |
10,000
-20.18%
|
$260,000
$26.06 P/Share
|
|
Nov 10
2022
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
25,000
-30.69%
|
$625,000
$25.57 P/Share
|
|
Nov 10
2022
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+23.48%
|
$75,000
$3.29 P/Share
|
|
Oct 03
2022
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
25,000
-30.69%
|
$625,000
$25.64 P/Share
|
|
Oct 03
2022
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+23.48%
|
$75,000
$3.29 P/Share
|
|
Sep 28
2022
|
Hazel Hunt Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
29,997
-29.08%
|
$779,922
$26.04 P/Share
|
|
Sep 28
2022
|
Hazel Hunt Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+32.65%
|
$100,000
$2.08 P/Share
|
|
Sep 07
2022
|
Gary Charles Robb Chief Business Officer |
SELL
Open market or private sale
|
Direct |
50,000
-50.23%
|
$1,300,000
$26.06 P/Share
|
|
Sep 01
2022
|
Gary Charles Robb Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,020
+1.01%
|
$24,240
$12.99 P/Share
|
|
Sep 01
2022
|
Sean Maduck |
BUY
Grant, award, or other acquisition
|
Direct |
1,844
+1.62%
|
$22,128
$12.99 P/Share
|
|
Sep 01
2022
|
Sean Maduck |
SELL
Open market or private sale
|
Direct |
25,000
-31.4%
|
$625,000
$25.84 P/Share
|
|
Sep 01
2022
|
Sean Maduck |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+23.9%
|
$75,000
$3.29 P/Share
|
|
Sep 01
2022
|
Atabak Mokari Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,586
+41.67%
|
$19,032
$12.99 P/Share
|
|
Sep 01
2022
|
William Guyer Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,844
+41.67%
|
$22,128
$12.99 P/Share
|